Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript
04:26pm, Thursday, 06'th Nov 2025
AstraZeneca PLC ( AZN ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Andrew Barnett - Head of Investor Relations Pascal Soriot - CEO & Executive Director Aradhana Sarin - CF
AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)
03:28pm, Thursday, 06'th Nov 2025
The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform
12:45pm, Thursday, 06'th Nov 2025
AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.
AstraZeneca climbs to net all-time high after US deal reassurance
11:21am, Thursday, 06'th Nov 2025
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted what analysts called a very solid set of third-quarter results, but the shares barely moved in early morning trading as the City waited for more details o
Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics
10:31am, Thursday, 06'th Nov 2025
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall
AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar
08:34am, Thursday, 06'th Nov 2025
AstraZeneca stock jumped Thursday after the drugmaker reported better-than-expected third-quarter sales and earnings.
AstraZeneca's 9M and Q3 2025 Financial Results
07:00am, Thursday, 06'th Nov 2025
CAMBRIDGE, England--(BUSINESS WIRE)--Q3 2025 Results Release.
AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO
04:12am, Thursday, 06'th Nov 2025
AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.
AstraZeneca grows faster than expected but maintains guidance
02:39am, Thursday, 06'th Nov 2025
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted a confident set of third-quarter results, not only beating revenue and core earnings forecasts, but also hailing "strong underlying momentum" across the b
AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal
02:39am, Thursday, 06'th Nov 2025
The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to $15.19 billion from $13.57 billion.
AstraZeneca beats third-quarter revenue and profit expectations
02:04am, Thursday, 06'th Nov 2025
AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London's most valuable listed company to retain its fu
Breakthrough Properties voltooit One Helix, een geavanceerde onderzoeksfaciliteit die volledig aan AstraZeneca is verhuurd
06:40pm, Wednesday, 05'th Nov 2025
/PRNewswire/ -- Breakthrough Properties, een toonaangevende wereldwijde ontwikkelaar van vastgoed ten behoeve van biowetenschappen, heeft vandaag de oplevering
AstraZeneca wins shareholder backing for NYSE listing in US pivot
11:11am, Monday, 03'rd Nov 2025
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US
11:06am, Monday, 03'rd Nov 2025
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first
